I work with a 2 similar but structurally different PEGylated polymeric nanoparticles encapsulating a traditional chemotherapeutic drug. The nanoparticles are developed to be administered orally. Preliminary efficacy studies shows good tumor control compared to free drug for both nanoparticle formulation. But size distribution studies of the drug encapsulated nanoparticles shows 2 peaks (suggesting breakdown of nanoparticles at acidic gastric pH), implying drug release as soon as nanoparticles reach stomach for one and significant difference in size (small size about 60 nm at pH 2, 120 nm at pH 7 and 150 nm size at pH 8) with a single peak for the other. What does these results imply? Why is there a size difference with pH.

More Sasidharan S Lucky's questions See All
Similar questions and discussions